Abstract
Objective: Prospective recording of IV nicardipine efficacy and safety as a first-line antihypertensive drug in neonates.¶Patients: Twenty neonates (15 preterm) with systemic hypertension due to steroids administration (n = 14), polycystic kidney disease (n = 1), renal vein thrombosis (n = 1), coarctation of aorta (n = 1) or from an undetermined cause (n = 3). Interventions: The initial nicardipine dosage was 0.5 μg/kg/min in 17 patients. The maximal nicardipine dosage was 0.74 ± 0.41 μg/kg/min (0.5–2.0). The duration of treatment was 14.6 ± 11.6 days. Results: Systolic blood pressure significantly decreased after 3, 6, 12, 24 and 48 h of nicardipine treatment (–20 ± 11 %, –19 ± 10 %, –20 ± 8 %, –20 ± 10 % and –20 ± 12 %, respectively). The decrease in blood pressure remained significant over the subsequent days of treatment. No hypotension or other clinical side effects were observed. Conclusions: Both additional pharmacokinetic and pharmacodynamic studies remain mandatory to improve the dosage regimens and assess the efficacy and safety of nicardipine infusion in hypertensive neonates.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 3 September 1999 Final revision received: 14 January 2000 Accepted: 27 January 2000
Rights and permissions
About this article
Cite this article
Milou, C., Debuche-Benouachkou, V., Semama, D. et al. Intravenous nicardipine as a first-line antihypertensive drug in neonates. Intensive Care Med 26, 956–958 (2000). https://doi.org/10.1007/s001340051287
Issue Date:
DOI: https://doi.org/10.1007/s001340051287